Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1975 Sep;72(9):3656–3660. doi: 10.1073/pnas.72.9.3656

Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.

A Lamensans, L Chedid, E Lederer, J P Rosselet, R H Gustafson, H J Spencer, B Ludwig, F M Berger
PMCID: PMC433055  PMID: 171670

Abstract

The data reported here demonstrate that a preparation extracted from nonpathogenic mycobacteria such as Mycobacterium smegmatis and hereafter referred to as interphase material protected mice against Ehrlich ascitic carcinoma, L-1210 leukemia, and another syngeneic lymphoid leukemia. Furthermore, mice treated by this preparation were much less susceptible to endotoxins than when stimulated by BCG (bacillus Calmette-Guerin) or M. smegmatis cells. Moreover, guinea pigs treated by interphase material administered in Freund's incomplete adjuvant showed an increased immune response, yet their sensitivity to tuberculin was much weaker than that of controls sensitized with Freund's complete adjuvant. Finally, resistance to Columbia SK virus infection could be demonstrated when interphase material was administered to mice prior to virus challenge.

Full text

PDF
3656

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam A., Ciorbaru R., Petit J. F., Lederer E. Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci U S A. 1972 Apr;69(4):851–854. doi: 10.1073/pnas.69.4.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azuma I., Ribi E. E., Meyer T. J., Zbar B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst. 1974 Jan;52(1):95–101. doi: 10.1093/jnci/52.1.95. [DOI] [PubMed] [Google Scholar]
  3. BIOZZI G., STIFFEL C., HALPERN B. N., MOUTON D. [Effect of inoculation with Calmette-Guerin bacillus on the development of Ehrlich ascites tumor in the mouse]. C R Seances Soc Biol Fil. 1959;153:987–989. [PubMed] [Google Scholar]
  4. Baldwin R. W., Pimm M. V. BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer. 1973 Sep 15;12(2):420–427. doi: 10.1002/ijc.2910120213. [DOI] [PubMed] [Google Scholar]
  5. Bekierkunst A., Levij I. S., Yarkoni E. Suppression of urethan-induced lung adenomas in mice treated with trehalose-6,6-dimycolate (cord factor) and living bacillus Calmette Guérin. Science. 1971 Dec 17;174(4015):1240–1242. doi: 10.1126/science.174.4015.1240. [DOI] [PubMed] [Google Scholar]
  6. Bekierkunst A., Levij I. S., Yarkoni E., Vilkas E., Lederer E. Cellular reaction in the footpad and draining lymph nodes of mice induced by mycobacterial fractions and BCG bacilli. Infect Immun. 1971 Sep;4(3):245–255. doi: 10.1128/iai.4.3.245-255.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bekierkunst A., Wang L., Toubiana R., Lederer E. Immunotherapy of Cancer with Nonliving BCG and Fractions Derived from Mycobacteria: Role of Cord Factor (Trehalose-6, 6'-Dimycolate) in Tumor Regression. Infect Immun. 1974 Nov;10(5):1044–1050. doi: 10.1128/iai.10.5.1044-1050.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chedid L., Lamensans A., Parant F., Parant M., Adam A., Petit J. F., Lederer E. Protective effects of delipidated mycobacterial cells and purified cell walls against Ehrlich carcinoma and a syngeneic lymphoid leukemia in mice. Cancer Res. 1973 Sep;33(9):2187–2195. [PubMed] [Google Scholar]
  9. Chedid L., Parant M., Parant F., Gustafson R. H., Berger F. M. Biological study of a nontoxic, water-soluble immunoadjuvant from mycobacterial cell walls. Proc Natl Acad Sci U S A. 1972 Apr;69(4):855–858. doi: 10.1073/pnas.69.4.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Erikson U., Hjelmstedt A. Roentgenologic aspects of BCG-osteomyelitis. Radiology. 1971 Dec;101(3):575–578. doi: 10.1148/101.3.575. [DOI] [PubMed] [Google Scholar]
  11. Hiu I. J. Water-soluble and lipid-free fraction from BCG with adjuvant and antitumour activity. Nat New Biol. 1972 Aug 23;238(86):241–242. doi: 10.1038/newbio238241a0. [DOI] [PubMed] [Google Scholar]
  12. Immunological aspects of neoplasia: a rational basis for immunotherapy. Ann Intern Med. 1971 Apr;74(4):587–604. doi: 10.7326/0003-4819-74-4-587. [DOI] [PubMed] [Google Scholar]
  13. Juy D., Bona C., Chedid L. Effet antitumoral de macrophages péritonéaux activés par un adjuvant hydrosoluble d'origine mycobactérienne. C R Acad Sci Hebd Seances Acad Sci D. 1974 May 27;278(22):2859–2862. [PubMed] [Google Scholar]
  14. Lamensans A., Mollier M. F., Laurent M. Action du BCG sur l'activité catalasique hépatique chez la souris. Relations avec le système réticulo-endothélial et la résistance a la leucose greffee AKR. Rev Fr Etud Clin Biol. 1968 Nov;13(9):871–876. [PubMed] [Google Scholar]
  15. Laucius J. F., Bodurtha A. J., Mastrangelo M. J., Creech R. H. Bacillus Calmette-Guerin in the treatment of neoplastic disease. J Reticuloendothel Soc. 1974 Dec;16(6):347–373. [PubMed] [Google Scholar]
  16. Mathé G. Active immunotherapy. Adv Cancer Res. 1971;14:1–36. doi: 10.1016/s0065-230x(08)60517-5. [DOI] [PubMed] [Google Scholar]
  17. Meyer T. J., Ribi E. E., Azuma I., Zbar B. Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J Natl Cancer Inst. 1974 Jan;52(1):103–111. doi: 10.1093/jnci/52.1.103. [DOI] [PubMed] [Google Scholar]
  18. Modolell M., Luckenbach G. A., Parant M., Munder P. G. The adjuvant activity of a mycobacterial water soluble adjuvant (WSA) in vitro. I. The requirement of macrophages. J Immunol. 1974 Jul;113(1):395–403. [PubMed] [Google Scholar]
  19. Mullarkey M. Letter: Viral photoinactivation and oncogenesis. N Engl J Med. 1974 Feb 7;290(6):343–343. doi: 10.1056/NEJM197402072900616. [DOI] [PubMed] [Google Scholar]
  20. OLD L. J., CLARKE D. A., BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
  21. SUTER E., ULLMAN G. E., HOFFMAN R. G. Sensitivity of mice to endotoxin after vaccination with BCG (Bacillus Calmette-Guérin). Proc Soc Exp Biol Med. 1958 Oct;99(1):167–169. doi: 10.3181/00379727-99-24282. [DOI] [PubMed] [Google Scholar]
  22. Sokal J. E., Aungst C. W., Han T. Use of Bacillus Calmette-Guérin as adjuvant in human cell vaccines. Cancer Res. 1972 Jul;32(7):1584–1589. [PubMed] [Google Scholar]
  23. Toullet F., Audibert F., Chedid L., Voisin G. A. Production d'une orchiépididymite aspermatogénétique autoimmune (oaai) chez le cobaye à laide d'un adjuvant hydrosoluble extrait de mycobacterium smegmatis. Ann Immunol (Paris) 1974 Nov;125(6):901–910. [PubMed] [Google Scholar]
  24. WEISS D. W., BONHAG R. S., DEOME K. B. Protective activity of fractions of tubercle bacilli against isologous tumours in mice. Nature. 1961 Jun 3;190:889–891. doi: 10.1038/190889a0. [DOI] [PubMed] [Google Scholar]
  25. Weiss D. W., Bonhag R. S., Leslie P. Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts. J Exp Med. 1966 Dec 1;124(6):1039–1065. doi: 10.1084/jem.124.6.1039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Zbar B., Bernstein I., Tanaka T., Rapp H. J. Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science. 1970 Dec 11;170(3963):1217–1218. doi: 10.1126/science.170.3963.1217. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES